Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Politikos on the Immune Reconstitution Profiles of Orca-T and CD34 Allograft Recipients in Hematologic Malignancies
April 1st 2025, 12:35pm
Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.
Post Hoc Analysis of Pooled PERSEUS and GRIFFIN Data Support D-VRd in Transplant-Eligible Myeloma
March 31st 2025, 9:31pm
D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.
TDI01 Demonstrates Preliminary Efficacy and Tolerability in Moderate-to-Severe cGVHD
March 31st 2025, 9:29pm
TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.
Acimtamig Plus AlloNK Elicits Responses in Heavily Pretreated R/R Hodgkin Lymphoma
March 31st 2025, 8:10pm
Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.
Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD
March 31st 2025, 8:07pm
A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.
Osimertinib After Definitive Chemoradiation Is New SOC for Unresectable Stage III EGFR+ NSCLC
March 31st 2025, 6:46pm
Longer-term outcomes from LAURA further support the benefit of osimertinib over placebo for patients with unresectable stage III EGFR-mutated NSCLC.
Orca-T Is Associated With Retrospective OS Improvement vs Post-Transplant Cyclophosphamide in Advanced Hematologic Malignancies
March 31st 2025, 6:39pm
Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.
Orca-T Stands Out From CD34 Grafts, Showing Lower Rates of EBV, CMV Reactivation in Hematologic Malignancies
March 31st 2025, 6:32pm
Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.
Optimized Tandem CD19/CD20–Directed CAR T Plus ASCT Elicits Durable Responses in R/R B-Cell Lymphomas
March 31st 2025, 5:47pm
Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.
Dr Hernández-Boluda on an EBMT Machine Learning Model for Identifying and Stratifying Transplant Risk in Myelofibrosis
March 31st 2025, 5:00pm
Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.
Effective Bridging Therapy Correlates With Improved PFS After Cilta-Cel in Multiple Myeloma
March 31st 2025, 4:54pm
Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.
Dr Olivia on the Phase 3 QuANTUM-Wild Trial of Quizartinib in Newly Diagnosed FLT3-ITD–Negative AML
March 31st 2025, 4:51pm
Esther Natalie Oliva, MD, discusses the rationale for the phase 3 QuANTUM-Wild trial in newly diagnosed FLT3-ITD–negative AML.
Hematologists Highlight Top Abstracts to Watch at the 2025 EBMT Annual Meeting
March 28th 2025, 2:00pm
Steven Devine, MD; Everett Meyer, MD, PhD; and Sophie Paczesny, MD, PhD, discuss their most highly anticipated presentations from the 2025 EBMT Meeting.
Nirogacestat Provides Long-Term Benefits in Desmoid Tumors
March 27th 2025, 8:00pm
ESMO Sarcoma and Rare Cancers Congress
Nirogacestat sustained long-term efficacy with acceptable safety in patients with desmoid tumors treated in the phase 3 DeFi trial.
Elective Discontinuation May Be Possible With Larotrectinib in TRK Fusion–Positive Sarcomas
March 27th 2025, 6:00pm
ESMO Sarcoma and Rare Cancers Congress
Pediatric patients with TRK fusion–positive sarcomas may be able to safely discontinue larotrectinib and resume treatment if needed without sacrificing response.
Frontline Amivantamab Plus Lazertinib Significantly Reduces Mortality in EGFR-Mutant Advanced NSCLC
March 27th 2025, 12:12pm
Amivantamab plus lazertinib provides long-term survival benefit over osimertinib in EGFR-mutated advanced non–small cell lung cancer.
Reduced Radiotherapy Margins Yield Outcomes Comparable With Standard Margins in HGG
March 24th 2025, 10:05pm
ESMO Sarcoma and Rare Cancers Congress
A randomized trial found no significant differences in recurrence or survival with smaller radiation margins vs standard RTOG protocols in patients with HGG.
Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma
March 24th 2025, 6:58pm
ESMO Sarcoma and Rare Cancers Congress
A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.
Physical Functioning Measures May Predict Survival Outcomes, ICANS Risk With CAR T-Cell Therapy in NHL
March 23rd 2025, 10:00am
Transplantation and Cellular Therapy Meetings
The risk of developing ICANS with CAR T-cell therapy was higher in patients with NHL who experienced a recent fall and could not balance on their left leg.
First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC
March 21st 2025, 12:00pm
Genitourinary Cancers Symposium (ASCO GU)
Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.